Source-verified
This database’s highest evidence status: the figure was read on the provider’s own published pricing page at the capture date and archived. The contrast classes — stated-not-verified, third-party-reported, no-price-published — are labeled on every record, because a ranking is only as honest as its worst-sourced number.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Where the term bites in the current data: the verified tirzepatide field runs $215–$597/month all-in and the semaglutide field $133–$348 (captured 2026-08-09), and nearly every dollar of those spreads is explained by the vocabulary on this glossary’s pages — memberships inside or outside headline figures, flat versus tiered ladders, prepaid terms dressed as monthly prices, evidence flags separating captures from claims. Reading this market is mostly a matter of knowing which of those words applies to the number in front of you.
It is the difference between the 17 programs the rankings will sort and the records they will only display. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.
See the term in action across the price database and the methodology.